reports
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology transforming the future of metabolic health, has received information on transactions in Zealand Phar...
VALLOUREC : Monthly information relating to the total number of voting...
VALLOUREC : Monthly information relating to the total number of voting rights and shares comprising the share capital VALLOURECFrench limited liability company (société anonyme) with a Board of Directors with share capital of € 4,768,147.86Registered office: 12, rue de la Verrerie – 92190 Meudon, FranceRegistered on the Nanterre Trade and Companies Register under n° 552 142 200 Meudon, December 19th, 2025 Monthly information relating to the total number of voting rightsand shares comprising the share capital Article L. 233-8-II of the French Code de commerce and Article 223-16 of the Gen...
VALLOUREC : Information mensuelle relative au nombre total de droits d...
VALLOUREC : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social VALLOURECSociété anonyme à Conseil d’Administrationau capital de 4 768 147,86 € Siège social : 12, rue de la Verrerie – 92190 Meudon552 142 200 RCS Nanterre Meudon, le 19 décembre 2025, Information mensuelle relative au nombre total de droits de voteet d’actions composant le capital social Article L. 233-8-II du Code de commerce et article 223-16 du Règlement Général de l’Autorité des Marchés Financiers DateNombre totald'actions en circulationNombre totalde droits de vote...
VALLOUREC ET GEOSTOCK SIGNENT UN ACCORD DE PARTENARIAT POUR ACCÉLÉRER ...
VALLOUREC ET GEOSTOCK SIGNENT UN ACCORD DE PARTENARIAT POUR ACCÉLÉRER LE DEVELOPPEMENT DE SOLUTIONS DE STOCKAGE À GRANDE ÉCHELLE POUR LA TRANSITION ÉNERGÉTIQUE VALLOUREC ET GEOSTOCK SIGNENT UN ACCORD DE PARTENARIAT POUR ACCÉLÉRER LE DEVELOPPEMENT DE SOLUTIONS DE STOCKAGEÀ GRANDE ÉCHELLE POUR LA TRANSITION ÉNERGÉTIQUE Meudon, le 18 décembre 2025 – Vallourec, leader mondial des solutions tubulaires premium sans soudure, et Geostock, spécialiste mondial du stockage souterrain d’énergie, ont signé un protocole d’accord (MoU) visant à renforcer leur collaboration dans le développement des...
VALLOUREC AND GEOSTOCK SIGN A PARTNERSHIP AGREEMENT TO ACCELERATE LARG...
VALLOUREC AND GEOSTOCK SIGN A PARTNERSHIP AGREEMENT TO ACCELERATE LARGE-SCALE STORAGE SOLUTIONS FOR THE ENERGY TRANSITION VALLOUREC AND GEOSTOCK SIGN A PARTNERSHIP AGREEMENT TO ACCELERATE LARGE-SCALE STORAGE SOLUTIONS FOR THE ENERGY TRANSITION Meudon, December 18, 2025 – Vallourec, a world leader in premium seamless tubular solutions, and Geostock, a global specialist in underground storage of energy, have signed a Memorandum of Understanding (MoU) to strengthen their collaboration in developing the infrastructure required for the energy transition, particularly for hydrogen and carbo...
- Jacob Mekhael
Zealand Pharma CMD key takeaways
Yesterday, Zealand Pharma hosted a CMD outlining its ambition to become a generational metabolic health company. The company highlighted key programs survodutide and petrelintide, and outlined plans to build a broader amylin franchise with plans for oral small molecule enabled by its newly announced collaboration with OTR therapeutics, as well as longer acting monthly amylin products. Zealand aims for five product launches in the next five years, and 10+ clinical pipeline programs by 2030. The c...
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78),), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 150,317 divided into 150,317 new shares with a nominal value of DKK 1 each. The capital i...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
- Mathijs Geerts Danau
Zealand Pharma Announces Metabolic Frontier 2030 strategy, and agreeme...
Zealand will host a CMD this afternoon to outline its Metabolic Frontier 2030 strategy to become a generational biotech leader in metabolic health. The company targets 5 launches, and 10+ clinical pipeline programs by 2030. In addition, the company announced a collaboration agreement with OTR therapeutics for the discovery of small molecule metabolic targets. We are encouraged by the clear targets and partnership with OTR therapeutics, demonstrating Zealand is willing to go beyond its usual area...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a g...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026New research si...
Zealand Pharma and OTR Therapeutics enter multi-program strategic coll...
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Press release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Collaboration will combine Zealand Pharma’s expertise in obesity and metabolic health with OTR Therapeutics’ proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 24 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 5, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received i...
AMENDMENT TO THE TERMS AND CONDITIONS OF THE WARRANTS
AMENDMENT TO THE TERMS AND CONDITIONS OF THE WARRANTS AMENDMENT TO THE TERMS AND CONDITIONS OF THE WARRANTS Meudon (France), on December 1st, 2025 – Vallourec announces that holders of warrants (“BSA”) (ISIN code: FR00140030K7), held today a general meeting, under the chairmanship of Aether, representative of the warrant holders. With a quorum of 100 % of warrant holders present, represented, or having voted by correspondence, the BSA holders have approved unanimously the amendment to the terms and conditions of the BSA, provided in the 1st resolution, in order to allow the delivery of new...
MODIFICATION DES TERMES ET CONDITIONS DES BSA
MODIFICATION DES TERMES ET CONDITIONS DES BSA MODIFICATION DES TERMES ET CONDITIONS DES BSA Meudon (France), le [1er] décembre 2025 – Vallourec annonce que les porteurs de bons de souscription d’actions (« BSA ») (code ISIN : FR00140030K7) réunis ce jour en assemblée générale, sous la présidence de Aether, représentant de la masse. Avec un quorum de 100 % de porteurs de BSA présents, représentés ou ayant voté par correspondance, les porteurs de BSA ont approuvé à l’unanimité la modification des termes et conditions des BSA, prévue à la 1ère résolution, afin de permettre la remise d’act...
REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025
REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Press release – No. 17 / 2025 REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Copenhagen, Denmark, December 1, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, is hosting a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity and metabolism. Time: December 11, 2025, from 1.00-5.30pm GMT (2.00-6.30pm CET)Venue: Goldman...
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
- Tanvi Arora
Lucror Analytics - Morning Views Europe
In today's Morning Views publication we comment on developments of the following high yield issuers: Profine, Vallourec, Tullow Oil, Polynt, Mehilainen, Altice International, Multiversity, Kantar, Odido, Fedrigoni, Kiloutou, Progroup, Stena AB, Picard, Loewen Play, Biofarma, Grunenthal, Sammontana Italia, Allwyn (formerly Sazka), Pfleiderer, Scan Global Logistics, Forvia (formerly Faurecia)
NATHALIE DELBREUVE IS APPOINTED AS CHIEF FINANCIAL OFFICER OF VALLOURE...
NATHALIE DELBREUVE IS APPOINTED AS CHIEF FINANCIAL OFFICER OF VALLOUREC AND JOINS THE EXECUTIVE COMMITTEE NATHALIE DELBREUVE IS APPOINTED ASCHIEF FINANCIAL OFFICER OF VALLOURECAND JOINS THE EXECUTIVE COMMITTEE Meudon (France), November 28, 2025 – Vallourec, a world leader in premium tubular solutions, announces today the appointment of Nathalie Delbreuve as Chief Financial Officer of the Group. She will join the Executive Committee and assume her new role as of December 1st, 2025. Nathalie Delbreuve was previously Chief Financial Officer of Verallia, the European leader and world’s third-...
NATHALIE DELBREUVE EST NOMMÉE DIRECTRICE FINANCIERE DE VALLOUREC ET RE...
NATHALIE DELBREUVE EST NOMMÉE DIRECTRICE FINANCIERE DE VALLOUREC ET REJOINT LE COMITE EXECUTIF DU GROUPE NATHALIE DELBREUVE EST NOMMÉEDIRECTRICE FINANCIERE DE VALLOURECET REJOINT LE COMITE EXECUTIF DU GROUPE Meudon (France), 28 novembre 2025 – Vallourec, leader mondial des solutions tubulaires premium sans soudure, annonce aujourd’hui la nomination de Nathalie Delbreuve au poste de Directrice financière du Groupe. Elle rejoint le Comité Exécutif et prendra ses fonctions le 1er décembre 2025. Nathalie Delbreuve était auparavant Directrice financière de Verallia, leader européen et troisièm...
VALLOUREC : Monthly information relating to the total number of voting...
VALLOUREC : Monthly information relating to the total number of voting rights and shares comprising the share capital VALLOURECFrench limited liability company (société anonyme) with a Board of Directors with share capital of € 4,768,147.86Registered office: 12, rue de la Verrerie – 92190 Meudon, FranceRegistered on the Nanterre Trade and Companies Register under n° 552 142 200 Meudon, November 28th, 2025 Monthly information relating to the total number of voting rightsand shares comprising the share capital Article L. 233-8-II of the French Code de commerce and Article 223-16 of the Gen...
VALLOUREC : Information mensuelle relative au nombre total de droits d...
VALLOUREC : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social VALLOURECSociété anonyme à Conseil d’Administrationau capital de 4 768 147,86 € Siège social : 12, rue de la Verrerie – 92190 Meudon552 142 200 RCS Nanterre Meudon, le 28 novembre 2025, Information mensuelle relative au nombre total de droits de voteet d’actions composant le capital social Article L. 233-8-II du Code de commerce et article 223-16 du Règlement Général de l’Autorité des Marchés Financiers DateNombre totald'actions en circulationNombre totalde droits de vote...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.